



(12) Translation of
European patent specification

(11) NO/EP 3285772 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/519 (2006.01)
A61P 37/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.02.17
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.10.02
(86)	European Application Nr.	16719356.4
(86)	European Filing Date	2016.04.20
(87)	The European Application's Publication Date	2018.02.28
(30)	Priority	2015.04.21, GB, 201506786
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	UCB Biopharma SRL, Allé de la Recherche 60, 1070 Brussels, Belgia
(72)	Inventor	ALLEN, Rodger Anthony, c/o IPD UCB Celltech 208 Bath Road, Slough Berkshire SL1 3WE, Storbritannia BARONE, Francesca, Rheumatology Research Group Institute of Inflammation and Ageing (IIA) University of Birmingham Queen Elizabeth Hospital, Birmingham B15 2WB, Storbritannia FAHY, William Anthony, c/o IPD UCB Celltech 208 Bath Road, Slough Berkshire SL1 3WE, Storbritannia NAYAR, Saba, Rheumatology Research Group Institute of Inflammation and Ageing (IIA) University of Birmingham Queen Elizabeth Hospital, Birmingham B15 2WB, Storbritannia
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	A SPECIFIC TRIFLUOROETHYL QUINOLINE ANALOGUE FOR USE IN THE TREATMENT OF SJÖGREN'S SYNDROME
------	-------	--

(56)	References Cited:	WO-A1-2012/032334 SIMON BOWMAN ET AL: "Biologic treatments in Sjögren's syndrome", PRESSE MEDICALE., vol. 41, no. 9, 1 September 2012 (2012-09-01), pages e495-e509, XP055281488, FR ISSN: 0755-4982, DOI: 10.1016/j.lpm.2012.05.024 BAUDOUIN C ET AL: "Current treatments of xerophthalmia in Sjögren's syndrome. // Traitements actuels de la xérophthalmia in Sjögren's syndrome", REVUE DE MEDECINE INTERNE, CMR, ASNIERES, FR, vol. 25, no. 5, 1 May 2004 (2004-05-01), pages 376-382, XP002684654, ISSN: 0248-8663, DOI: 10.1016/J.REVMED.2003.10.009
------	----------------------	--

Anonymous: "UCB Proof of Concept Study in Patients With Primary Sjogren's Syndrome", , 18 November 2015 (2015-11-18), XP002758921, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/NC_T02610543?term=ucb_5857&rank=3 [retrieved on 2016-06-17]
NAYAR, S ET AL.: "Phosphatidylinositol-3-kinase Delta Parthway a Novel Therapeutic Target for Sjögren's Syndrome", ARTHRITIS AND RHEUMATOLOGY, vol. 67, no. 10, 1053, October 2015 (2015-10), XP002758920,
YAGER, N. ET AL.: "Inhibition of phosphatidylinositol-3-kinase delta reduces psoriatic T cell activity", Journal of Investigative Dermatology, vol. 134, no. 2, 418, July 2014 (2014-07), page s73, XP002758922, Retrieved from the Internet: URL:http://ac.els-cdn.com/S0022202X15370160/1-s2.0-S0022202X15370160-main.pdf?_tid=05c9f640-3492-11e6-b6f6-00000aabb0f6b&acdnat=1466171424_7b2a8ae7df72912d692f8f848363d1_97 [retrieved on 2016-06-17]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. *N*-{(R)-1-[8-klor-2-(1-oksypyridin-3-yl)kinolin-3-yl]-2,2,2-trifluoetyl}pyrido[3,2-
5 *d*]pyrimidin-4-ylamin, eller et farmasøytisk akseptabelt salt derav, for anvendelse i
behandling og / eller forebygging av Sjogrens syndrom.
2. Forbindelse for anvendelse ifølge krav 1, hvor Sjögren's syndrom er primært Sjögrens
syndrom.